This company has been acquired
Provention Bio Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Información clave
-36.7%
Tasa de crecimiento de los beneficios
-7.1%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 6.0% |
| Tasa de crecimiento de los ingresos | 97.9% |
| Rentabilidad financiera | -93.2% |
| Margen neto | -880.7% |
| Última actualización de beneficios | 31 Dec 2022 |
Actualizaciones de resultados anteriores recientes
Recent updates
Provention Bio appoints O'Brien as Chief People Officer
Sep 19Provention Bio secures $125M term loan facility
Sep 01Provention Bio: More Risk, More Dilution Ahead - Downgrading To A Sell Rating
Aug 12Provention Bio Q2 2022 Earnings Preview
Aug 03Provention Bio to raise $60M through private placement of securities
Jul 08Provention Bio says FDA extends review period for co's teplizumab application to Nov. 17
Jun 30Provention Bio (PRVB): BLA Accepted; Downgrading To A Hold
Mar 31Provention Bio: Upgrading To A Strong-Buy, Potential Cure For Type 1 Diabetes
Feb 04Is Provention Bio (NASDAQ:PRVB) In A Good Position To Invest In Growth?
Jan 11
Is Provention Bio (NASDAQ:PRVB) In A Good Position To Deliver On Growth Plans?
Aug 26Provention Bio: Blood (Glucose) In The Streets
Jul 30FDA Advisory Committee supports Provention Bio's teplizumab in delaying diabetes
May 28Provention Bio EPS misses by $0.05
May 06Provention Bio provides regulatory update on teplizumab BLA
Apr 27How Much Of Provention Bio, Inc. (NASDAQ:PRVB) Do Insiders Own?
Mar 17Need To Know: Provention Bio, Inc. (NASDAQ:PRVB) Insiders Have Been Buying Shares
Feb 10
Provention Bio prices $100M stock offering
Jan 14Provention Bio Could See Meaningful Upside Once Teplizumab Hits The Market
Jan 07Provention Bio (NASDAQ:PRVB) Is In A Good Position To Deliver On Growth Plans
Jan 06Provention Bio files US application for its diabetes drug
Jan 04Provention Bio launches first-in-human PRV-101 study in coxsackievirus B
Dec 15Is Provention Bio, Inc.'s (NASDAQ:PRVB) Shareholder Ownership Skewed Towards Insiders?
Dec 02Provention Bio EPS misses by $0.14
Nov 05Desglose de ingresos y gastos
Cómo gana y gasta dinero Provention Bio. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Dec 22 | 13 | -114 | 64 | 0 |
| 30 Sep 22 | 3 | -106 | 51 | 0 |
| 30 Jun 22 | 3 | -105 | 48 | 0 |
| 31 Mar 22 | 2 | -104 | 47 | 0 |
| 31 Dec 21 | 1 | -114 | 47 | 0 |
| 30 Sep 21 | 1 | -121 | 48 | 0 |
| 30 Jun 21 | 0 | -125 | 48 | -24 |
| 31 Mar 21 | 0 | -118 | 42 | -9 |
| 31 Dec 20 | 0 | -99 | 33 | 0 |
| 30 Sep 20 | 0 | -77 | 24 | 8 |
| 30 Jun 20 | 0 | -55 | 17 | 40 |
| 31 Mar 20 | 0 | -45 | 11 | 35 |
| 31 Dec 19 | 0 | -43 | 8 | 0 |
| 30 Sep 19 | 0 | -38 | 7 | 33 |
| 30 Jun 19 | 0 | -34 | 5 | 30 |
| 31 Mar 19 | 0 | -33 | 5 | 28 |
| 31 Dec 18 | 0 | -27 | 4 | 23 |
| 30 Sep 18 | 0 | -25 | 4 | 21 |
| 30 Jun 18 | 0 | -21 | 3 | 17 |
| 31 Mar 18 | 0 | -15 | 2 | 12 |
| 31 Dec 17 | 0 | -9 | 1 | 8 |
Ingresos de calidad: PRVB is currently unprofitable.
Margen de beneficios creciente: PRVB is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: PRVB is unprofitable, and losses have increased over the past 5 years at a rate of 36.7% per year.
Acelerando crecimiento: Unable to compare PRVB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: PRVB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.6%).
Rentabilidad financiera
Alta ROE: PRVB has a negative Return on Equity (-93.2%), as it is currently unprofitable.